Twist Bioscience Sets Date to Report Fiscal 2026 Results
Twist Bioscience will report its fiscal 2026 fourth-quarter and full-year results.
Related stories
Akamai Prices Convertible Senior Notes Offering
M impact | EQUITY | Nov 10, 2026, 02:52 AM UTC
Ennostar Reports Third-Quarter Net Profit of NT$1.28 Billion
Ennostar reported third-quarter revenue of NT$6.686503 billion, compared with NT$5.602991 billion a year earlier. Net profit was NT$1.28 billion, versus a net loss of NT$615.9 mill
M impact | EQUITY | Nov 10, 2026, 02:40 AM UTC
Akamai Prices $2.2B in Convertible Notes Due 2028 and 2031
Akamai priced $1.1 billion of 1.00% convertible notes due 2028 and $1.1 billion due 2031. It may issue up to $150 million more of each series. Estimated net proceeds are $2,164.2 m
M impact | EQUITY | Nov 10, 2026, 02:37 AM UTC
Sunrex Technology Reports NT$4.46 Million Third-Quarter Net Loss
Sunrex Technology reported a net loss of NT$4.46 million for the quarter ended Sept. 30, versus net profit of NT$255.9 million a year earlier. Revenue and pretax profit were lower
M impact | EQUITY | Nov 10, 2026, 02:36 AM UTC
BOJ Estimates ¥1 Trillion in Annual Proceeds From Faster ETF Sales
Finance Minister Satsuki Katayama said the BOJ expects accelerated sales of its ETF holdings to generate about 1 trillion yen ($6.33 billion) in additional annual proceeds.
L impact | EQUITY | Nov 10, 2026, 02:31 AM UTC
Rocket Lab Shares Fall After Q3 Loss Miss; Neutron Price Rises to $70 Million
Rocket Lab reported a wider-than-expected third-quarter loss, while Neutron’s base launch price rose to $70 million and its next available launch slots stretched into the 2030s. Sh
M impact | EQUITY | Nov 10, 2026, 02:30 AM UTC